President Trump’s HHS Nomination A Bitter Pill for Seniors

“The resignation of HHS Secretary Tom Price in September presented an opportunity for President Trump to select a nominee who would champion quality, affordable health care for all Americans, including seniors. Instead, he has tapped a former Big Pharma executive, Alex Azar. This is an ironic choice for a President who has pledged to lower prescription drug prices. As President of Eli Lilly, Azar presided over frequent price hikes on medications that seniors on fixed incomes depend upon. In fact, the company is currently being sued for fixing the price of insulin. Equally discouraging is Azar’s support of reckless legislation to repeal and replace the Affordable Care Act. Like his predecessor, Azar would be an unreliable steward of Medicare and Medicaid, which the GOP-led Congress has proposed to cut despite the President’s promise to protect both programs. This appointment is yet another example of President Trump restocking the pond with corporate chieftains instead of draining the swamp. Seniors and their families should vigorously oppose it.”
– Max Richtman, President and CEO of the National Committee to Preserve Social Security and Medicare